Pantop%25252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. ## Primary Indications * Erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Short-term treatment of GERD symptoms in adults. ## Adult Dosing * **Erosive Esophagitis (Treatment):** 40 mg PO or IV once daily for up to 8 weeks. * **Erosive Esophagitis (Maintenance):** 40 mg PO once daily. * **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been utilized; titrate based on clinical response. * **GERD (Short-term):** 20 mg PO once daily for 4 weeks. ## Pediatric Dosing * **Erosive Esophagitis (Children ≥ 5 years):** * 15 kg to < 40 kg: 20 mg PO once daily. * ≥ 40 kg: 40 mg PO once daily. * Duration: Up to 8 weeks. * **Note:** IV administration in pediatric patients is not well-established for all conditions; consult local institutional protocols. ## Dose Adjustments * **Renal Impairment:** No dosage adjustment necessary. * **Hepatic Impairment:** Use with caution in severe hepatic impairment; monitor closely. Maximum daily dose should not exceed 20 mg for mild-to-moderate impairment, or consider 40 mg every other day in severe cases, pending clinician discretion. ## Contraindications * Hypersensitivity to pantoprazole or other substituted benzimidazoles. * Concomitant use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, injection site reactions (if IV). * **Serious:** *Clostridioides difficile*-associated diarrhea, acute interstitial nephritis, hypomagnesemia, Vitamin B12 deficiency (with long-term use), bone fractures (risk associated with long-term/high-dose use). ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic gastric pH (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil). * **CYP2C19 Inhibitors/Inducers:** Methotrexate levels may be increased. * **Warfarin:** Monitor INR frequently when initiating or discontinuing PPIs due to potential changes in metabolism. ## Monitoring * Monitor for signs of *C. difficile* diarrhea (e.g., persistent watery stool). * Re-evaluate treatment necessity periodically; avoid indefinite use unless clinically mandated. * For long-term therapy (>1 year): Monitor magnesium levels, Vitamin B12 status, and bone density. ## Clinical Pearls * **Administration:** PO tablets should be swallowed whole; do not crush or chew. IV administration must be performed via slow injection or infusion to prevent thrombophlebitis. * **De-prescribing:** PPIs are frequently over-prescribed. Assess for discontinuation or de-escalation to H2 receptor antagonists if the initial indication has resolved. * **Uncertainty:** Optimal duration of high-dose therapy for hypersecretory conditions remains highly individualized; reliance on local institutional or expert guidelines is recommended. *** **Disclaimer:** This information is for educational purposes and does not substitute for professional medical judgment. Always verify current prescribing information, institutional guidelines, and drug formulary updates before administration.